URI: 
   DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: BRIUMVI (ublituximab)
       *****************************************************
       #Post#: 3335--------------------------------------------------
       Ublituximab "reassuring" as potential relapsing MS
       therapy
   DIR By: agate
       Date: June 30, 2021, 6:47 pm
       ---------------------------------------------------------
       From Multiple Sclerosis News Today (June 30, 2021)--"Ublituximab
       'Quite Reassuring' as Potential RMS Therapy, Experts Say":
  HTML https://multiplesclerosisnewstoday.com/news-posts/2021/06/30/ublituximab-tg-therpeutics-potential-relapsing-ms-therapy-interview-article/
       #Post#: 3424--------------------------------------------------
       Ublituximab up for FDA approval
   DIR By: agate
       Date: October 2, 2021, 1:04 am
       ---------------------------------------------------------
       From Multiple Sclerosis News Today (October 1,
       2021)--"Ublituximab, Potential Relapsing MS Therapy, Up for FDA
       Approval":
  HTML https://multiplesclerosisnewstoday.com/news-posts/2021/10/01/tg-therapeutics-asks-fda-approval-ublituximab-relapsing-ms/
       #Post#: 3687--------------------------------------------------
       (CMSC) Ubilituximab tied to slowed disease progression in
       relapsing MS
   DIR By: agate
       Date: June 18, 2022, 1:19 am
       ---------------------------------------------------------
       From Medscape Today (June 10, 2022)--"Novel drug tied to slowed
       disease progression in relapsing MS":
  HTML https://www.medscape.com/viewarticle/975368
       #Post#: 3755--------------------------------------------------
       (Abst.) Ublituximab vs. teriflunomide in relapsing MS
   DIR By: agate
       Date: August 27, 2022, 1:35 am
       ---------------------------------------------------------
       From PubMed (August 25, 2022), citing a New England Journal of
       Medicine article, "Ublituximab versus teriflunomide in relapsing
       multiple sclerosis":
  HTML https://pubmed.ncbi.nlm.nih.gov/36001711/
       *****************************************************
       Page 1 of 1